NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)
NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma